Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

Sleep Apnea, Obstructive Clinical Trial

— PACE  

Official title:

Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01755091
• Other study ID #: 2012-0095
• Secondary ID: UM1HL112856
• Status: Completed
• Phase: Phase 2
• Start date: February 2013
• Est. completion date: December 31, 2016

Study information

• Verified date: July 2021
• Source: University of Illinois at Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a proof of concept study to determine the safety and efficacy of dronabinol for the treatment of obstructive sleep apnea syndrome (OSA).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: December 31, 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 64 Years

Eligibility

Inclusion Criteria:

• Adult 21 to 64 years of age;

• 15=AHI = 50 on screening polysomnogram (PSG)

• ESS score = 7

• Able to understand and complete informed consent and all study assessments and forms, presented in an English-speaking format;

• Women of child-bearing potential (WCBP) must have a negative urine pregnancy test. In addition sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria:

• Arterial oxygen saturation < 75% for > 5% of sleep period time on screening PSG;

• Occupation or life situation that may impart risk by study participation (e.g. commercial driver, pilot, police officer, fireman);

• Motor vehicle accident or "near-miss" related to sleepiness (self-report) within 2 years of the first dose of study drug (Day 8);

• Body mass index > 45 kg/m2

• Severe obstructive sleep apnea syndrome (OSAS) that, based on the clinical judgment of the Investigator, precludes delaying positive airway pressure treatment;

• History of shift work or rotating shifts within the month prior to the first dose of study drug (Day 8);

• Prior upper airway surgery for snoring or OSAS as an adult (= 18 years of age);

• Prior non-invasive treatment for OSAS within 6 months prior to the first dose of study drug (Day 8);

• Major surgery within 6 months prior to the first dose of study drug (Day 8);

• Bariatric surgery within 2 years prior to the first dose of study drug (Day 8). If post-bariatric surgery, weight must be stable ±5% (self-report) for at least 6 months prior to first dose of study drug (Day 8).

• Any form of medically managed weight loss program within 6 months prior to the first dose of study drug (Day 8);

• Significant defect in nasal patency due to anatomical abnormalities or uncontrolled or recurrent episodes of rhinitis;

• Any clinically significant unstable or progressive medical condition;

• Any primary sleep disorder other than OSAS as determined by history, physical examination, or Visit 2 PSG (after 7-day screening run-in period);

• Clinically significant or uncontrolled: chronic obstructive pulmonary disease (COPD), cardiovascular disease, gastrointestinal, respiratory, pancreatic, hepatic, renal, hematologic, endocrine [including insulin-dependent diabetes mellitus (IDDM)], neurological, urogenital, connective tissue, dermatological, thyroid, or other medical disorder;

• Any clinically significant psychiatric disorder;

• History of seizure disorder;

• Treatment with any prescription antidepressant medication within 1 month prior to the first dose of study drug (Day 8);

• Treatment with sedatives, hypnotics or other psychoactive drugs within 30 days prior to the first dose of study drug (Day 8);

• Any complete blood count (CBC) or liver function test (LFT) laboratory value outside the normal range which, in the clinical judgment of the Investigator renders a subject inappropriate for randomization to treatment;

• Pregnancy [as demonstrated by positive urine human chorionic gonadotropin (hCG) test] or lactation;

• Allergic to cannabinoids or sesame oil;

• History of substance abuse (including alcohol abuse or dependence) or laboratory evidence of drug abuse on the Visit 1 drug-screening panel;

• Use of dietary supplements which in the judgment of the Investigator may impact sleep or breathing behaviors;

• Average daily caffeine consumption > 500 mg/day (~5 cups of coffee);

• Average weekly alcohol consumption > 10 units;

• Unwillingness to abstain from caffeine and alcohol on all days when overnight or daytime testing will be performed;

• Participation in any other investigational protocol within the 30 days prior to the first dose of study drug (Day 8);

• Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he or she were to participate in the study.

Related Conditions & MeSH terms

• Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Drug:
• Dronabinol

• Placebo (for Dronabinol)

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	University of Illinois at Chicago	Chicago	Illinois

Sponsors (5)

Lead Sponsor	Collaborator
University of Illinois at Chicago	Hektoen Institute for Medical Research, National Heart, Lung, and Blood Institute (NHLBI), Northwestern University, University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Apnea/Hypopnea Index (AHI)	Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)	Baseline and Week 6
Primary	Change in Epworth Sleepiness Scale (ESS)	Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales.	Baseline and Week 6
Primary	Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)	Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time.	Baseline and Week 6
Secondary	Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM) Overall Score.	The TSQM measures a person's satisfaction with treatment based on a 7-point scale ranging from "Extremely Dissatisfied" to "Extremely Satisfied" in response to the question, "Taking all things into account, how satisfied or dissatisfied are you with this medication?".	Week 6
Secondary	Adverse Events (AEs)	AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)	Up to 8 weeks
Secondary	Change in Desaturation Time (DT)	Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)	6 weeks